The molecular characterization of von Willebrand disease: Good in parts

British Journal of Haematology

Volumn 161, Issue 2, 2013, Pages 166-176

  James, P D ^a   Lillicrap, D ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Factor VIII; Von Willebrand disease; Von Willebrand factor

Indexed keywords

DESMOPRESSIN;

ABO GENE; DISEASE CLASSIFICATION; DRUG EFFICACY; ENVIRONMENTAL FACTOR; EXON; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; LINKAGE ANALYSIS; MISSENSE MUTATION; MOLECULAR PATHOLOGY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOGENE; RECESSIVE INHERITANCE; REVIEW; TREATMENT RESPONSE; VON WILLEBRAND DISEASE; VWF GENE;

GENETIC LOCI; HUMANS; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND DISEASE, TYPE 3; VON WILLEBRAND FACTOR;

EID: 84875812623     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12249     Document Type: Review

References (77)

1. Bellissimo, D.B., Christopherson, P.A., Flood, V.H., Gill, J.C., Friedman, K.D., Haberichter, S.L., Shapiro, A.D., Abshire, T.C., Leissinger, C., Hoots, W.K., Lusher, J.M., Ragni, M.V. & Montgomery, R.R. (2012) Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood, 119, 2135-2140.
2. Campos, M., Sun, W., Yu, F., Barbalic, M., Tang, W., Chambless, L.E., Wu, K.K., Ballantyne, C., Folsom, A.R., Boerwinkle, E. & Dong, J.-F. (2011) Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood, 117, 5224-5230.
3. Canis, K., McKinnon, T.A., Nowak, A., Panico, M., Morris, H.R., Laffan, M. & Dell, A. (2010) The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. Journal of Thrombosis and Haemostasis, 8, 137-145.
4. Canis, K., McKinnon, T., Nowak, A., Haslam, S.M., Panico, M., Morris, H.R., Laffan, M.A. & Dell, A. (2012) Mapping the N-glycome of human von Willebrand factor. The Biochemical Journal, 447, 217-228.
5. Casonato, A., Sartorello, F., Cattini, M.G., Pontara, E., Soldera, C., Bertomoro, A. & Girolami, A. (2003) An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood, 101, 151-156.
6. Castaman, G., Lethagen, S., Federici, A.B., Tosetto, A., Goodeve, A., Budde, U., Batlle, J., Meyer, D., Mazurier, C., Fressinaud, E., Goudemand, J., Eikenboom, J., Schneppenheim, R., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Pasi, J., Hill, F., Peake, I. & Rodeghiero, F. (2008) Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 111, 3531-3539.
7. Castaman, G., Tosetto, A. & Rodeghiero, F. (2009) Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. Journal of Thrombosis and Haemostasis, 7(Suppl 1), 71-74.
8. Castaman, G., Castaman, G., Federici, A.B., Tosetto, A., La Marca, S., Stufano, F., Mannucci, P.M. & Rodeghiero, F. (2012) Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. Journal of Thrombosis and Haemostasis, 10, 632-638.
9. Chandler, W.L., Peerschke, E.I.B., Castellone, D.D. & Meijer, P. (2011) Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. American Journal of Clinical Pathology, 135, 62-869.
10. Conlan, M.G., Folsom, A.R., Finch, A., Davis, C.E., Sorlie, P., Marcucci, G. & Wu, K.K. (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thrombosis and Haemostasis, 70, 380-385.
11. Coppola, R., Mari, D., Lattuada, A. & Franceschi, C. (2003) Von Willebrand factor in Italian centenarians. Haematologica, 88, 39-43.
12. Cumming, A., Grundy, P., Keeney, S., Lester, W., Enayat, S., Guilliatt, A., Bowen, D., Pasi, J., Keeling, D., Hill, F., Bolton-Maggs, P.H., Hay, C. & Collins, P. (2006) An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thrombosis and Haemostasis, 96, 630-641.
13. Dalton, R.G., Dewar, M.S., Savidge, G.F., Kernoff, P.B., Matthews, K.B., Greaves, M. & Preston, F.E. (1987) Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet, 1, 1007-1009.
14. De Lange, M., Snieder, H., Ariëns, R.A., Spector, T.D. & Grant, P.J. (2001) The genetics of haemostasis: a twin study. Lancet, 357, 101-105.
15. Eikenboom, J.C. (2001) Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Practice and Research. Clinical Haematology, 14, 365-379.
16. Eikenboom, J., Van Marion, V., Putter, H., Goodeve, A., Rodeghiero, F., Castaman, G., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., Schneppenheim, R., Budde, U., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Lethagen, S., Pasi, J., Hill, F., Hashemi Soteh, M., Baronciani, L., Hallden, C., Guilliatt, A., Lester, W. & Peake, I. (2006) Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. Journal of Thrombosis and Haemostasis, 4, 774-782.
17. Eikenboom, J., Hilbert, L., Ribba, A.S., Hommais, A., Habart, D., Messenger, S., Al-Buhairan, A., Guilliatt, A., Lester, W., Mazurier, C., Meyer, D., Fressinaud, E., Budde, U., Will, K., Schneppenheim, R., Obser, T., Marggraf, O., Eckert, E., Castaman, G., Rodeghiero, F., Federici, A.B., Batlle, J., Goudemand, J., Ingerslev, J., Lethagen, S., Hill, F., Peake, I. & Goodeve, A. (2009) Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. Journal of Thrombosis and Haemostasis: JTH, 7, 1304-1312.
18. Favaloro, E.J. (2010) Genetic testing for von Willebrand disease: the case against. Journal of Thrombosis and Haemostasis, 8, 6-12.
19. Federici, A.B., Mannucci, P.M., Castaman, G., Baronciani, L., Bucciarelli, P., Canciani, M.T., Pecci, A., Lenting, P.J. & De Groot, P.G. (2008) Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood, 113, 526-534.
20. Flood, V.H., Lederman, C.A., Wren, J.S., Christopherson, P.A., Friedman, K.D., Hoffmann, R.G. & Montgomery, R.R. (2010) Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. Journal of Thrombosis and Haemostasis: JTH, 8, 1431-1433.
21. Flood, V.H., Gill, J.C., Christopherson, P.A., Wren, J.S., Friedman, K.D., Haberichter, S.L., Hoffmann, R.G. & Montgomery, R.R. (2012a) Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. Journal of Thrombosis and Haemostasis: JTH, 10, 1425-1432.
22. Flood, V.H., Gill, J.C., Christopherson, P.A., Bellissimo, D.B., Friedman, K.D., Haberichter, S.L., Lentz, S.R. & Montgomery, R.R. (2012b) Critical von Willebrand factor A1 domain residues influence type VI collagen binding. Journal of Thrombosis and Haemostasis: JTH, 10, 1417-1424.
23. Gallinaro, L., Cattini, M.G., Sztukowska, M., Padrini, R., Sartorello, F., Pontara, E., Bertomoro, A., Daidone, V., Pagnan, A. & Casonato, A. (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood, 111, 3540-3545.
24. Gill, J.C., Endres-Brooks, J., Bauer, P.J., Marks, W.J. Jr & Montgomery, R.R. (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood, 69, 1691-1695.
25. Ginsburg, D., Handin, R.I., Bonthron, D.T., Donlon, T.A., Bruns, G.A., Latt, S.A. & Orkin, S.H. (1985) Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science, 228, 1401-1406.
26. Goodeve, A., Eikenboom, J., Castaman, G., Rodeghiero, F., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., Schneppenheim, R., Budde, U., Ingerslev, J., Habart, D., Vorlova, Z., Holmberg, L., Lethagen, S., Pasi, J., Hill, F., Hashemi, S.M., Baronciani, L., et al (2007) Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 109, 112-121.
27. Haberichter, S.L., Balistreri, M., Christopherson, P., Morateck, P., Gavazova, S., Bellissimo, D.B., Manco-Johnson, M.J., Gill, J.C. & Montgomery, R.R. (2006) Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood, 108, 3344-3351.
28. Haberichter, S.L., Castaman, G., Budde, U., Peake, I., Goodeve, A., Rodeghiero, F., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., Eikenboom, J., Schneppenheim, R., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Lethagen, S., Pasi, J., Hill, F.G. & Montgomery, R.R. (2008) Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood, 111, 4979-4985.
29. Huizinga, E.G., Tsuji, S., Romijn, R.A., Schiphorst, M.E., De Groot, P.G., Sixma, J.J. & Gros, P. (2002) Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science, 297, 1176-1179.
30. Jackson, S.C., Sinclair, G.D., Cloutier, S., Duan, Z., Rand, M.L. & Poon, M.-C. (2009) The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood, 113, 3348-3351.
31. Jacobi, P.M., Gill, J.C., Flood, V.H., Jakab, D.A., Friedman, K.D. & Haberichter, S.L. (2012) Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood, 119, 4543-4553.
32. James, P.D., Paterson, A.D., Notley, C., Cameron, C., Hegadorn, C., Tinlin, S., Brown, C., O'Brien, L., Leggo, J. & Lillicrap, D. (2006) Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. Journal of Thrombosis and Haemostasis, 4, 783-792.
33. James, P.D., Notley, C., Hegadorn, C., Poon, M.C., Walker, I., Rapson, D. & Lillicrap, D. (2007a) Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. Journal of Thrombosis and Haemostasis, 5, 1914-1922.
34. James, P.D., Notley, C., Hegadorn, C., Leggo, J., Tuttle, A., Tinlin, S., Brown, C., Andrews, C., Labelle, A., Chirinian, Y., O'Brien, L., Othman, M., Rivard, G., Rapson, D., Hough, C. & Lillicrap, D. (2007b) The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood, 109, 145-154.
35. Koppelman, S.J., van, H.M., Vink, T., Lankhof, H., Schiphorst, M.E., Damas, C., Vlot, A.J., Wise, R., Bouma, B.N. & Sixma, J.J. (1996) Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood, 87, 2292-2300.
36. Liu, L., Wang, X., Lin, Z. & Wu, H. (1993) Elevated plasma levels of VWF:Ag in hyperthyroidism are mediated through beta-adrenergic receptors. Endocrine Research, 19, 123-133.
37. Lynch, D.C., Zimmerman, T.S., Collins, C.J., Brown, M., Morin, M.J., Ling, E.H. & Livingston, D.M. (1985) Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell, 41, 49-56.
38. Lyons, S.E., Bruck, M.E., Bowie, E.J. & Ginsburg, D. (1992) Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. Journal of Biological Chemistry, 267, 4424-4430.
39. Mancuso, D.J., Tuley, E.A., Westfield, L.A., Lester-Mancuso, T.L., Le Beau, M.M., Sorace, J.M. & Sadler, J.E. (1991) Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry, 30, 253-269.
40. Mannucci, P.M., Ruggeri, Z.M., Ciavarella, N., Kazatchkine, M.D. & Mowbray, J.F. (1981) Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. Blood, 57, 25-31.
41. Mannucci, P.M., Lombardi, R., Castaman, G., Dent, J.A., Lattuada, A., Rodeghiero, F. & Zimmerman, T.S. (1988) von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood, 71, 65-70.
42. Mazurier, C. (1992) von Willebrand disease masquerading as haemophilia A. Thrombosis and Haemostasis, 67, 391-396.
43. Mazurier, C., Goudemand, J., Hilbert, L., Caron, C., Fressinaud, E. & Meyer, D. (2001) Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Practice and Research. Clinical Haematology, 14, 337-347.
44. Meijer, P. & Haverkate, K. (2006) An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Seminars in Thrombosis and Hemostasis, 32, 485-491.
45. Meyer, D., Fressinaud, E., Gaucher, C., Lavergne, J.M., Hilbert, L., Ribba, A.S., Jorieux, S. & Mazurier, C. (1997) Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thrombosis and Haemostasis, 78, 451-456.
46. Mohl, A., Marschalek, R., Masszi, T., Nagy, E., Obser, T., Oyen, F., Sallai, K., Bodo, I. & Schneppenheim, R. (2008) An Alu-mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary. Journal of Thrombosis and Haemostasis: JTH, 6, 1729-1735.
47. Montgomery, R.R. (2006) When it comes to von Willebrand disease, does 1 + 1 = 3? Journal of Thrombosis and Haemostasis: JTH, 4, 2162-2163.
48. Montgomery, R.R., Christopherson, P.A., Haberichter, S.L., Flood, V.H., Gill, J.C. & The Zimmerman Program Investigators (2011) Diagnostic Fidelity of Historically Diagnosed Patients with VWD Enrolled from 27 Centers in the ZPMCB-VWD. ASH Annual Meeting Abstracts, 118, 381.
49. Ngo, K.Y., Glotz, V.T., Koziol, J.A., Lynch, D.C., Gitschier, J., Ranieri, P., Ciavarella, N., Ruggeri, Z.M. & Zimmerman, T.S. (1988) Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proceedings of the National Academy of Sciences of the USA, 85, 2753-2757.
50. Nichols, W.L., Hultin, M.B., James, A.H., Manco-Johnson, M.J., Montgomery, R.R., Ortel, T.L., Rick, M.E., Sadler, J.E., Weinstein, M. & Yawn, B.P. (2008) von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia, 14, 171-232.
51. Nilsson, I.M., Blomback, M., Jorpes, E., Blomback, B. & Johansson, S.A. (1957) Von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Medica Scandinavica, 159, 179-188.
52. O'Brien, L.A., James, P.D., Othman, M., Berber, E., Cameron, C., Notley, C.R., Hegadorn, C.A., Sutherland, J.J., Hough, C., Rivard, G.E., O'Shaunessey, D. & Lillicrap, D. (2003) Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood, 102, 549-557.
53. Orstavik, K.H. (1990) Genetics of plasma concentration of von Willebrand factor. Folia Haematologica (Leipzig, Germany: 1928), 117, 527-531.
54. Othman, M. (2007) Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Seminars in Thrombosis and Hemostasis, 33, 780-786.
55. Peake, I.R. & Goodeve, A.C. (2010) Genetic testing for von Willebrand disease: the case for. Journal of Thrombosis and Haemostasis, 8, 13-16.
56. Peake, I.R., Bloom, A.L. & Giddings, J.C. (1974) Inherited variants of factor-VIII-related protein in von Willebrand's disease. The New England Journal of Medicine, 291, 113-117.
57. Pottinger, B.E., Read, R.C., Paleolog, E.M., Higgins, P.G. & Pearson, J.D. (1989) von Willebrand factor is an acute phase reactant in man. Thrombosis Research, 53, 387-394.
58. Pruss, C.M., Golder, M., Bryant, A., Hegadorn, C.A., Burnett, E., Laverty, K., Sponagle, K., Dhala, A., Notley, C., Haberichter, S. & Lillicrap, D. (2011) Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood, 117, 4358-4366.
59. Ribba, A.S., Loisel, I., Lavergne, J.M., Juhan-Vague, I., Obert, B., Cherel, G., Meyer, D. & Girma, J.P. (2001) Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thrombosis and Haemostasis, 86, 848-854.
60. Riddell, A., Gomez, K., Millar, C., Mellars, G., Brown, S., Gill, S., Laffan, M. & McKinnon, T.A.J. (2009) Characterisation of W1745C and S1783A, two novel collagen binding defects in the A3 domain of von Willebrand factor. Blood, 114, 3489-3496.
61. Ruggeri, Z.M. (2004) Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. Journal of Thrombosis and Haemostasis, 2, 2-6.
62. Ruggeri, Z.M., Pareti, F.I., Mannucci, P.M., Ciavarella, N. & Zimmerman, T.S. (1980) Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. The New England Journal of Medicine, 302, 1047-1051.
63. Sadler, J.E. (1998) Biochemistry and genetics of von Willebrand factor. Annual Review of Biochemistry, 67, 395-424.
64. Sadler, J.E. (2003) Von Willebrand disease type 1: a diagnosis in search of a disease. Blood, 101, 2089-2093.
65. Sadler, J.E., Shelton-Inloes, B.B., Sorace, J.M., Harlan, J.M., Titani, K. & Davie, E.W. (1985) Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proceedings of the National Academy of Sciences of the USA, 82, 6394-6398.
66. Sadler, J.E., Budde, U., Eikenboom, J.C., Favaloro, E.J., Hill, F.G., Holmberg, L., Ingerslev, J., Lee, C.A., Lillicrap, D., Mannucci, P.M., Mazurier, C., Meyer, D., Nichols, W.L., Nishino, M., Peake, I.R., Rodeghiero, F., Schneppenheim, R., Ruggeri, Z.M., Srivastava, A., Montgomery, R.R. & for the Working Party on von Willebrand Disease Classification (2006) Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of Thrombosis and Haemostasis, 4, 2103-2114.
67. Shelton-Inloes, B.B., Chehab, F.F., Mannucci, P.M., Federici, A.B. & Sadler, J.E. (1987) Gene deletions correlate with the development of alloantibodies in von Willebrand disease. Journal of Clinical Investigation, 79, 1459-1465.
68. Smith, N.L., Chen, M.H., Dehghan, A., Strachan, D.P., Basu, S., Soranzo, N., Hayward, C., Rudan, I., Sabater-Lleal, M., Bis, J.C., De Maat, M.P., Rumley, A., Kong, X., Yang, Q., Williams, F.M., Vitart, V., Campbell, H., Malarstig, A., Wiggins, K.L., Van Duijn, C.M., et al (2010) Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation, 121, 1382-1392.
69. Sporn, L.A., Chavin, S.I., Marder, V.J. & Wagner, D.D. (1985) Biosynthesis of von Willebrand protein by human megakaryocytes. Journal of Clinical Investigation, 76, 1102-1106.
70. Sutherland, M.S., Cumming, A.M., Bowman, M., Bolton-Maggs, P.H.B., Bowen, D.J., Collins, P.W., Hay, C.R.M., Will, A.M. & Keeney, S. (2009) A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood, 114, 1091-1098.
71. Tsai, H.M. (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 87, 4235-4244.
72. Verweij, C.L., De Vries, C.J., Distel, B., Van Zonneveld, A.J., Van Kessel, A.G., Van Mourik, J.A. & Pannekoek, H. (1985) Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Research, 13, 4699-4717.
73. Von Willebrand, E.A. (1926) Hereditar pseudohemofili. Finska Lakaresallskapets Handlingar, LXVII, 87-112.
74. Wagner, D.D. & Marder, V.J. (1983) Biosynthesis of von Willebrand protein by human endothelial cells: identification of a large precursor polypeptide chain. Journal of Biological Chemistry, 258, 2065-2067.
75. Zhang, Z.P., Blomback, M., Nyman, D. & Anvret, M. (1993) Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands. Proceedings of the National Academy of Sciences of the USA, 90, 7937-7940.
76. Zhang, X., Halvorsen, K., Zhang, C.-Z., Wong, W.P. & Springer, T.A. (2009) Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science (New York, NY), 324, 1330-1334.
77. Zimmerman, T.S., Ratnoff, O.D. & Powell, A.E. (1971) Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against anti. The Journal of Clinical Investigation, 50, 244-254.